The FTSE 100 is down today, but Halma investors aren’t panicking

With the FTSE 100 down, Halma’s share price has barely budged today after it announced acquisitions. Is it worth buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life-saving technology group Halma (FTSE: HLMA) announced today that it had made another couple of acquisitions, NovaBone and FireMate. These will sit beside the other five companies bought by the group in its 2019 financial year. If you look back to at least 2014, there’s not one year in which it failed to make an acquisition.

The group increases its revenues and profits through a combination of acquisitions, partnerships and organic growth. Buying other companies is a fundamental part of its strategy, which has helped its share price go pretty much straight up for the last five years.

The shares’ longer-term performance is also encouraging. Shareholders enjoyed a total return of 1,141% from March 2009 to March 2019.

Fitting in

If the acquirer does its due diligence and doesn’t overpay for an acquisition that fits well with the company’s activities, then buying-in revenues and profits can add value for shareholders.

Of the two acquisitions announced today, one is a US-based designer and manufacturer of bone grafts, the other deals in cloud-based fire protection maintenance software for fire contractors.

Halma organises its businesses into four major segments: process, safety, infrastructure safety, environmental & analysis, and medical. The bone graft business fits nicely into the surgical applications subdivision of medical and the fire protection business slots into the fire subdivision of the infrastructure segment.

Looks like a bargain

NovaBone, the bone graft business, is being bought for approximately £74m in upfront cash, with up to £31m in add-ons depending on performance.

The group is paying about 14 to 20 times EBITDA for NovaBone (well below the 22.67 times average for the healthcare products industry). The price depends on performance and the new owner has forecast revenue and EBITDA of £16m and £5.3m respectively at its newly-acquired business. The price looks cheap to me.

Getting a 70% share of FireMate’s software business will cost Halma £6.2m upfront, with £3.3 in contingent payments. There’s an option to purchase the remaining shares exercisable in 2025.

Halma’s proportional share of FireMate’s last 12 months of EBIT would have been £0.35m and it’s paying 18 to 27 times EBIT for a controlling stake. Again, this multiple looks cheap compared to the 36 or 54 times EBIT averages paid for internet and system & application businesses.

The website Damodaran Online was used to find industry averages.

Not a bootstrapper

These are small acquisitions for Halma. Yet it’s encouraging to note that it doesn’t appear to be overpaying for businesses that fit well with existing operations.

Another issue with deal-hungry companies is that they sometimes buy growth to conceal weakness in their existing operations. According to Halma’s 2019 report, organic, constant currency growth ranged from 6.9% to 11.3% across its four divisions.

Organic, constant currency growth removes the distortions caused by acquisitions and exchange rate fluctuations. What it tells investors is that the group was growing well in 2019 before adding in acquired revenue. Since the pound weakened over the year, revenue growth on a non-constant-currency basis was even better.

At 2,161p, shares in Halma are not exactly cheap at 44 times consensus 2020 earnings of 49.6p. The forecast dividend yield is 0.8%, which is not awe-inspiring either. However, dividends and profits have grown by 7% and 13%, respectively, on average, over four years.

At the time of writing the FTSE 100 is down 2.4% but Halma’s share price has barely budged. For the long-term investor, the share looks like a good deal to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK has recommended Halma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »